Jun L. Kang
Guangzhou, 510630, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
Efficacy and safety of triptorelin acetate microspheres for injection versus triptorelin acetate for injection in Chinese patients with endometriosis: a multicenter, randomized, double-blind, phase Ⅲ non-inferiority clinical trial
Journal: Zhonghua fu chan ke za zhi
Published: January 29, 2026
EphB4/EphrinB2 signaling regulates pericyte-like function of DPSCs in angiogenesis via transcriptional factor SRF.
Journal: Stem cell research & therapy
Published: January 10, 2026
Comment on "Precise biometric measurement of the mouse eye using optical coherence tomography based on optic-nerve-head imaging".
Journal: Experimental eye research
Published: January 05, 2026
Soft substrate priming erases fibrotic mechanical memory in mesenchymal stromal cells via YAP lysosomal degradation to improve therapeutic efficacy for spinal cord injury.
Journal: Biomaterials
Published: January 04, 2026
Efficacy and safety of combined nebulization of unfractionated heparin, acetylcysteine, budesonide and ipratropium bromide in hospitalised patients with COVID-19 pneumonia: a randomized controlled clinical trial.
Journal: BMC pulmonary medicine
Published: May 15, 2025
Ischemia-free liver transplantation as a novel approach to improve survival and clinical outcomes in the acute-on-chronic liver failure scenario.
Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
Published: March 26, 2025
Tissue bridges offer valuable insights into bladder and bowel outcomes in chronic cervical spinal cord injury.
Journal: European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
Published: March 11, 2025
Anti-EGFR therapy can overcome acquired resistance to the third-generation ALK-tyrosine kinase inhibitor lorlatinib mediated by activation of EGFR.
Journal: Acta pharmacologica Sinica
Published: December 03, 2024
Last Updated: 09/26/2026